Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· July 10, 2026

Pfizer (PFE) Gets An Opening In ATTR CM After AstraZeneca Trial Failure

View original at finance.yahoo.com

Pfizer (PFE) Gets An Opening In ATTR CM After AstraZeneca Trial Failure Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

AstraZeneca reported a phase III failure for its ATTR-CM drug Wainua, shifting attention to competitors in this rare heart disease segment.
60% confidence
The news challenges the idea that Pfizer must rely heavily on additional partnerships or acquisitions to offset every patent expiry, since an existing franchise appears to have gained relative strength without new deal-making.
60% confidence
Simply Wall St has flagged 4 risks for Pfizer that could impact investment.
60% confidence
This news supports the narrative that Pfizer's late-stage rare-disease portfolio can contribute to long-term resilience by reducing near-term competitive pressure around ATTR-CM.
60% confidence
AstraZeneca's phase III setback gives Pfizer fresh room to defend and possibly extend its ATTR-CM heart disease position without spending on a new deal.
60% confidence